Johnson&Johnson brings over 100 innovative products to the CIIE, with nearly a quarter of them making their debut at the first show
六月清晨搅
发表于 4 小时前
114
0
0
The 7th China International Import Expo is coming soon. As a "full-time student" at the CIIE, Johnson&Johnson will focus on the two major business segments of medical technology and innovative pharmaceuticals with the theme of "Innovation in Action, Caring in Heart", showcasing over a hundred innovative products in Hall 7.2 of the medical device and healthcare exhibition area. About a quarter of them will be the first to showcase their products.
At this year's CIIE, Johnson&Johnson's booth has set up a dedicated star product exhibition area, showcasing cutting-edge innovative products including 2 "global debuts" and over 20 "China debuts and debuts". In the field of innovative pharmaceuticals, Rybrevant, a bispecific antibody, is used to treat adult patients with non-small cell lung cancer; reg; Ze Beike, the first and currently the only compound preparation in China for the treatment of BRCA mutant metastatic castration resistant prostate cancer; reg; Waiting for heavyweight exhibits to appear. In the field of medical technology, MONARCH& reg; Impella, a heavyweight innovative product in the field of natural cavity diagnosis and treatment robots and heart failure treatment; reg; CP with SmartAssist interventional left ventricular assist pump, Pronova& for minimally invasive cardiovascular surgery; reg; Suture, innovative paddle design disposable magnetic positioning mapping catheter OPTRELL, MatrixORTHOGNATIC LOCK orthopedic internal fixation system designed specifically for patients with malocclusion in Asia, and TECNISOdyssey innovative intraocular lens designed to provide full range vision; reg; Waiting for cutting-edge medical technology products and solutions from around the world.
At the same time, Johnson&Johnson's medical technology business is innovating in the intersection of biology and technology. Its exhibition area focuses on the fields of surgery, cardiovascular and cerebrovascular diseases, orthopedics, and eye health, bringing a series of more intelligent, minimally invasive, and personalized innovative products and solutions. Through physical exhibitions and multimedia interactive devices, visitors can experience Johnson&Johnson's medical products and technologies firsthand.
The CIIE is an important measure taken by the government to promote high-level opening up to the outside world, support high-quality development, and create a better business environment, "said Zhou Mintao, President of Johnson&Johnson Medical Technology China
Johnson&Johnson's innovative pharmaceutical business is committed to scientifically exploring the future of the pharmaceutical industry. Its exhibition area focuses on heavyweight products in the fields of oncology, immunology, neuroscience, and cardiovascular diseases, fully demonstrating its innovative concept of putting science first, mission first, and patient first, as well as its mission to bring new hope to patients.
Cherry Huang, President of Johnson&Johnson Innovative Pharmaceuticals China, said, "The CIIE is the 'spotlight' for many innovative drugs, the 'catalyst' for promoting cooperation among all parties, and the 'booster' for enterprise development. For Johnson&Johnson Innovative Pharmaceuticals, the CIIE is not only an important opportunity to showcase its numerous innovative drugs and breakthrough therapies, but also an important platform to deepen understanding of the Chinese medical and health market, promote exchanges and cooperation in the medical and health industry. We look forward to using the CIIE platform to accelerate the introduction of more globally leading innovative drugs into China, serve the health needs of more Chinese patients, and promote the continuous development of the medical and health industry
Johnson&Johnson said that in the future, the company will continue to take root in China, give full play to the role of a leader in the medical and health industry, seize the new opportunities brought by market development, while accelerating innovative research and development, actively promote local innovation cooperation, help improve the accessibility and affordability of innovative medical and health products and solutions, and constantly make new positive contributions to the high-quality development of Chinese people's health and medical and health industry.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
-
10月23日、新東方は2025年度第1財季(2024年6月1日から8月31日)の財報を発表した。特筆すべきは、董宇輝が新東方を去った後、東方が選んだ初の季報だ。その中で、新東方はわざわざ東方が自社製品をオーディション ...
- 什么大师特
- 1 小时前
- 支持
- 反对
- 回复
- 收藏
-
国内の革新的な薬企業がまた1発の深水爆弾を爆発させた。 10月25日、国内革新薬企業「一兄」百済神州大中華区の殷敏首席商務官が規制当局の調査を受けていることがメディアに暴露され、業界関係者がメディアにこの ...
- 刘moon
- 2 小时前
- 支持
- 反对
- 回复
- 收藏
-
米国疾病管理・予防センターはこのほど、マクドナルドの「足三両」バーガーが同国西部の大腸菌疫病の発生と関係があり、49人が病気になり、1人が死亡したと明らかにした。マクドナルドは声明を発表し、大腸菌の疫病 ...
- SOHU
- 前天 09:34
- 支持
- 反对
- 回复
- 收藏
-
10月24日、テスラ米株式市場は12%以上上昇し、第3四半期の利益は予想を上回った。マースク氏は来年の自動車販売台数が20%-30%増加すると予測している。 ...
- 就放荡不羁就h
- 昨天 17:35
- 支持
- 反对
- 回复
- 收藏